MedTrace Logo

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

NCT04397692 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2022-12-16

No results posted yet for this study

Summary

The purpose of this open label, randomized, study is to obtain information on the safety and efficacy of 80 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.

Conditions

  • Corona Virus Infection
  • COVID-19
  • SARS-CoV 2
  • Nitric Oxide
  • Respiratory Disease
  • Pneumonia, Viral
  • Inhaled Nitric Oxide

Interventions

DEVICE

Nitric Oxide delivered via LungFit™ system

Patients will receive inhalations of 80 ppm for 40 min 4 times a day

Sponsors & Collaborators

  • Beyond Air Inc.

    lead INDUSTRY

Principal Investigators

  • Ashik Tal, MD · Beyond Air

Study Design

Allocation
RANDOMIZED
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-13
Primary Completion
2020-09-30
Completion
2020-09-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04397692 on ClinicalTrials.gov